Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1158 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Mylan introduces generic Depakote Sprinkle capsules

Mylan‘s Divalproex Sodium capsules USP, 125mg are the generic version of Abbott’s Depakote Sprinkle capsules, indicated for the treatment of certain types of seizures. Depakote Sprinkle capsules are

Eisai gets Japanese approval for pediatric drug

Vasolan is a calcium channel blocking agent which suppresses tachyarrhythmia by blocking the influx of calcium ions into cells and slowing cardiac excitation. Currently, Eisai seeks to establish

Biogen Idec FAMPYRA receives EMA positive opinion

FAMPYRA is a prolonged-release (sustained release) tablet formulation of the drug fampridine (4-aminopyridine, 4-AP or dalfampridine). The CHMP recommended the conditional marketing authorisation of FAMPYRA to improve walking

Vectura Q1 revenue increases

Vectura‘s net income operating income was £13.3m, compared to £15.3m for the same period in 2010. The company’s gross profit increased by 10% to £40.2m (2009/10: £36.6m). Vectura

Tibotec HIV drug receives FDA approval

Edurant, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is used as part of a highly active antiretroviral therapy (HAART) regimen that is designed to suppress the amount of HIV

China Ruitai sees fall in Q1 sales

China Ruitai’s net income was $735,893, or $0.03 per diluted share, compared to net income of $1.94m, or $0.07 per diluted share, for the comparable period last year.